MM
MCID: MYL069
MIFTS: 85

Myeloma, Multiple (MM)

Categories: Blood diseases, Bone diseases, Cancer diseases, Genetic diseases, Nephrological diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Myeloma, Multiple

MalaCards integrated aliases for Myeloma, Multiple:

Name: Myeloma, Multiple 57 38 40
Multiple Myeloma 57 12 75 53 25 59 74 37 29 13 6 43 44 15 17 72 33
Plasma Cell Myeloma 12 53 59 55
Medullary Plasmacytoma 25 59 72
Plasma Cell Dyscrasia 53 25 72
Myelomatosis 53 25 59
Multiple Myeloma, Resistance to 57 6
Primary Systemic Amyloidosis 59 72
Primary Amyloidosis 59 72
Kahler's Disease 25 59
Kahler Disease 53 25
Multiple Myeloma, Susceptibility to 57
Immunoglobulin Deposition Disease 72
Systemic Al Amyloidosis 59
Light-Chain Amyloidosis 59
Kahler-Bozzolo Disease 25
Plasma Cell Myelomas 25
Plasma Cell Neoplasm 72
Amyloidosis Primary 55
Myeloma - Multiple 53
Al Amyloidosis 59
Mm 74

Characteristics:

Orphanet epidemiological data:

59
primary systemic amyloidosis
Inheritance: Not applicable;
multiple myeloma
Prevalence: 1-9/100000 (United States),1-9/100000 (Worldwide),1-5/10000 (Europe),1-9/100000 (France),1-9/100000 (Europe),1-9/100000 (Australia); Age of onset: Adult;
al amyloidosis
Inheritance: Not applicable; Prevalence: 1-5/10000 (Europe); Age of onset: Adult;

OMIM:

57
Inheritance:
somatic mutation


HPO:

32
myeloma, multiple:
Inheritance autosomal recessive inheritance somatic mutation


Classifications:



External Ids:

Disease Ontology 12 DOID:9538
OMIM 57 254500
KEGG 37 H00010
ICD9CM 35 203.0
MeSH 44 D009101
NCIt 50 C3242
SNOMED-CT 68 55921005 94705007
ICD10 33 C90.0 C90.00
MESH via Orphanet 45 C531616 D009101
ICD10 via Orphanet 34 C90.0 E85.0 E85.1 more
UMLS via Orphanet 73 C0026764 C0268381
UMLS 72 C0026764 C0268381 C0281479 more

Summaries for Myeloma, Multiple

Genetics Home Reference : 25 Multiple myeloma is a cancer that develops in the bone marrow, the spongy tissue found in the center of most bones. The bone marrow produces red blood cells, which carry oxygen throughout the body; white blood cells, which form the body's defenses (immune system); and platelets, which are necessary for blood clotting. Multiple myeloma is characterized by abnormalities in plasma cells, a type of white blood cell. These abnormal cells multiply out of control, increasing from about one percent of cells in the bone marrow to the majority of bone marrow cells. The abnormal cells form tumors within the bone, causing bone pain and an increased risk of fractures. If the tumors interfere with nerves near the bones, numbness or weakness in the arms or legs can occur. Affected individuals may also experience a loss of bone tissue, particularly in the skull, spine, ribs, and pelvis. The deterioration of bone can result in an excess of calcium in the blood (hypercalcemia), which can lead to nausea and loss of appetite, excessive thirst, fatigue, muscle weakness, and confusion. The abnormal plasma cells in multiple myeloma produce proteins that impair the development of normal blood cells. As a result, affected individuals may have a reduced number of red blood cells (anemia), which can cause fatigue, weakness, and unusually pale skin (pallor); a low number of white blood cells (leukopenia), which can result in a weakened immune system and frequent infections such as pneumonia; and a reduced number of platelets (thrombocytopenia), which can lead to abnormal bleeding and bruising. Kidney problems can also occur in this disorder, caused by hypercalcemia or by toxic proteins produced by the abnormal plasma cells. People with multiple myeloma typically develop the disorder around age 65. Over time, affected individuals can develop life-threatening complications, but the rate at which this happens varies widely. Some affected individuals are diagnosed incidentally when tests are done for other purposes and do not experience symptoms for years.

MalaCards based summary : Myeloma, Multiple, also known as multiple myeloma, is related to leukemia, chronic lymphocytic and leukemia, acute myeloid. An important gene associated with Myeloma, Multiple is LIG4 (DNA Ligase 4), and among its related pathways/superpathways are Transcriptional misregulation in cancer and Cytokine Signaling in Immune system. The drugs Apixaban and Phentolamine have been mentioned in the context of this disorder. Affiliated tissues include Blood and Blood, and related phenotypes are osteopenia and pathologic fracture

Disease Ontology : 12 A myeloid neoplasm that is located in the plasma cells in bone marrow.

NIH Rare Diseases : 53 Multiple myeloma is a form of cancer that occurs due to abnormal and uncontrolled growth of plasma cells in the bone marrow. Some people with multiple myeloma, especially those with early stages of the condition, have no concerning signs or symptoms. When present, the most common symptom is anemia, which can be associated with fatigue and shortness of breath. Other features of the condition may include multiple infections; abnormal bleeding; bone pain; weak and/or easily broken bones; and numbness and/or weakness of the arms and legs. The exact underlying cause of multiple myeloma is currently unknown. Factors that are associated with an increased risk of developing multiple myeloma include increasing age, male sex, African American race, radiation exposure, a family history of the condition, obesity, and/or a personal history of monoclonal gammopathy of undetermined significance (MGUS). Treatment varies based on many factors, but may include one or more of the following interventions: chemotherapy, corticosteroid medications, targeted therapy, stem cell transplant, biological therapy, radiation therapy, surgery and/or watchful waiting.

OMIM : 57 Multiple myeloma is a neoplastic plasma cell disorder characterized by clonal proliferation of malignant plasma cells in the bone marrow microenvironment, monoclonal protein in the blood or urine, and associated organ dysfunction (Palumbo and Anderson, 2011). (254500)

MedlinePlus : 43 Multiple myeloma is a cancer that begins in plasma cells, a type of white blood cell. These cells are part of your immune system, which helps protect the body from germs and other harmful substances. In time, myeloma cells collect in the bone marrow and in the solid parts of bones. No one knows the exact causes of multiple myeloma, but it is more common in older people and African Americans. It can run in families. Common symptoms may include Bone pain, often in the back or ribs Broken bones Weakness or fatigue Weight loss Frequent infections and fevers Feeling very thirsty Frequent urination Doctors diagnose multiple myeloma using lab tests, imaging tests, and a bone marrow biopsy. Your treatment depends on how advanced the disease is and whether you have symptoms. If you have no symptoms, you may not need treatment right away. If you have symptoms, you may have chemotherapy, stem cell transplantation, radiation, or targeted therapy. Targeted therapy uses substances that attack cancer cells without harming normal cells. NIH: National Cancer Institute

KEGG : 37
Multiple myeloma is a disorder in which malignant plasma cells accumulate, generally derived from one clone in the bone marrow. Intricate interactions occur between the bone-marrow microenvironment and the myeloma cells, frequently causing bone destruction, which in turn stimulates tumor growth. Often it is preceded by a premalignant tumor called monoclonal gammopathy of undetermined significance (MGUS). Multiple oncogenic events have been identified that have contributed to the pathogenesis of myeloma. Among the earliest genetic events are translocations of the immunoglobulin heavy-chain gene locus, which leads to dysregulation of oncogenes at translocation partner regions (cyclin D1 at 11q13, FGFR3/MMSET at 4p16.3, c-MAF at 16q23, and cyclin D3 at 6p21), and deletions of 13q14, the site of a putative tumor suppressor gene. Additional molecular events include epigenetic changes and activation of oncogenes (mutations of N-RAS and K-RAS, and changes in c-MYC), which are usually associated with disease progression.

UniProtKB/Swiss-Prot : 74 Multiple myeloma: A malignant tumor of plasma cells usually arising in the bone marrow and characterized by diffuse involvement of the skeletal system, hyperglobulinemia, Bence-Jones proteinuria and anemia. Complications of multiple myeloma are bone pain, hypercalcemia, renal failure and spinal cord compression. The aberrant antibodies that are produced lead to impaired humoral immunity and patients have a high prevalence of infection. Amyloidosis may develop in some patients. Multiple myeloma is part of a spectrum of diseases ranging from monoclonal gammopathy of unknown significance (MGUS) to plasma cell leukemia.

Wikipedia : 75 Multiple myeloma (MM), also known as plasma cell myeloma, is a cancer of plasma cells, a type of white... more...

Related Diseases for Myeloma, Multiple

Diseases related to Myeloma, Multiple via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1764)
# Related Disease Score Top Affiliating Genes
1 leukemia, chronic lymphocytic 33.1 TP53 PTPN11 NRAS MIR19A KRAS HRAS
2 leukemia, acute myeloid 32.9 TP53 PTPN11 NRAS MIR181A2 KRAS IDH2
3 myeloid leukemia 32.7 TP53 PTPN11 NRAS IDH1 HRAS
4 lymphoma, non-hodgkin, familial 32.6 TP53 NRAS CCND1 BRAF
5 adenocarcinoma 32.4 TP53 KRAS HRAS FGFR3 CDK4 CCND1
6 hepatocellular carcinoma 32.4 TP53 NRAS MIR93 MIR25 MIR19A MIR181A2
7 skin melanoma 32.3 TP53 NRAS BRAF
8 colorectal cancer 32.3 TP53 NRAS MIR93 MIR32 MIR25 MIR19A
9 bladder cancer 32.3 TP53 KRAS HRAS FGFR3 CDK4 CCND1
10 lung cancer 32.2 TP53 NRAS MIR93 MIR32 MIR19A MIR15A
11 prostate cancer 32.2 TP53 MIR32 MIR25 MIR15A MIR106B KRAS
12 glioblastoma 32.2 TP53 NRAS MIR25 MIR181A2 IDH2 IDH1
13 lung cancer susceptibility 3 32.2 TP53 NRAS KRAS IDH1 HRAS FGFR3
14 pancreatic cancer 32.1 TP53 MIR32 MIR25 MIR181A2 MIR15A KRAS
15 melanoma 32.1 TP53 NRAS MIR19A MIR181A2 MIR15A CDK4
16 suppression of tumorigenicity 12 31.9 TP53 IDH1 HRAS BRAF
17 large intestine cancer 31.9 TP53 PTPN11 NRAS KRAS IDH2 IDH1
18 endometrial cancer 31.9 TP53 KRAS HRAS CDK4 CCND1 BRAF
19 myelodysplastic syndrome 31.8 TP53 PTPN11 NRAS KRAS IDH2 IDH1
20 glioblastoma multiforme 31.8 TP53 IDH1 CDK4 CCND1
21 squamous cell carcinoma 31.8 TP53 HRAS FGFR3 CCND1 BRAF
22 cholangiocarcinoma 31.8 TP53 KRAS IDH2 IDH1 CCND1 BRAF
23 gastric adenocarcinoma 31.8 TP53 NRAS KRAS HRAS CCND1 BRAF
24 transitional cell carcinoma 31.8 TP53 HRAS FGFR3 BRAF
25 intrahepatic cholangiocarcinoma 31.7 TP53 KRAS IDH2 IDH1
26 thyroid cancer, nonmedullary, 1 31.7 MIR181A2 MIR15A BRAF
27 gastrointestinal stromal tumor 31.6 TP53 KRAS CCND1 BRAF
28 ovarian cancer 31.6 TP53 MIR106B KRAS CDK4 CCND1 BRAF
29 nasopharyngeal carcinoma 31.6 TP53 NRAS HRAS CDK4 CCND1
30 glioma 31.5 TP53 MIR25 MIR19A MIR181A2 MIR15A IDH2
31 plasma cell leukemia 31.5 FGFR3 CCND1
32 brain cancer 31.5 TP53 PTPN11 NRAS MIR25 IDH2 IDH1
33 bladder urothelial carcinoma 31.5 TP53 NRAS KRAS IDH1 HRAS FGFR3
34 colorectal adenoma 31.5 TP53 KRAS HRAS
35 squamous cell carcinoma, head and neck 31.5 TP53 MIR19A MIR15A IDH2 HRAS FGFR3
36 adenoma 31.5 TP53 KRAS CCND1 BRAF
37 gastric cancer 31.4 TP53 MIR93 MIR25 MIR106B KRAS CCND1
38 sarcoma 31.4 TP53 KRAS HRAS CDK4 BRAF
39 nervous system cancer 31.4 TP53 IDH2 IDH1 CDK4 CCND1
40 medulloblastoma 31.4 TP53 NRAS MIR19A IDH1 CDK4 CCND1
41 differentiated thyroid carcinoma 31.4 TP53 NRAS KRAS HRAS BRAF
42 carcinosarcoma 31.4 TP53 KRAS HRAS
43 nevus, epidermal 31.4 NRAS KRAS HRAS FGFR3
44 testicular germ cell tumor 31.4 TP53 HRAS FGFR3 BRAF
45 ovarian serous cystadenocarcinoma 31.3 TP53 NRAS HRAS BRAF
46 hyperplastic polyposis syndrome 31.3 TP53 KRAS BRAF
47 acneiform dermatitis 31.3 NRAS KRAS HRAS
48 bladder disease 31.2 TP53 FGFR3 CCND1
49 kidney cancer 31.1 TP53 MIR15A MIR106B
50 esophageal cancer 31.1 TP53 KRAS HRAS CDK4 CCND1

Graphical network of the top 20 diseases related to Myeloma, Multiple:



Diseases related to Myeloma, Multiple

Symptoms & Phenotypes for Myeloma, Multiple

Human phenotypes related to Myeloma, Multiple:

59 32 (show top 50) (show all 84)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 osteopenia 59 32 hallmark (90%) Very frequent (99-80%) HP:0000938
2 pathologic fracture 59 32 hallmark (90%) Very frequent (99-80%) HP:0002756
3 nephropathy 59 32 frequent (33%) Frequent (79-30%),Frequent (79-30%) HP:0000112
4 fatigue 59 32 frequent (33%) Frequent (79-30%),Very frequent (99-80%) HP:0012378
5 generalized muscle weakness 59 32 frequent (33%) Frequent (79-30%) HP:0003324
6 anemia 59 32 frequent (33%) Frequent (79-30%) HP:0001903
7 decreased antibody level in blood 59 32 frequent (33%) Frequent (79-30%),Occasional (29-5%) HP:0004313
8 nephrotic syndrome 59 32 frequent (33%) Frequent (79-30%),Frequent (79-30%) HP:0000100
9 elevated serum creatinine 59 32 frequent (33%) Frequent (79-30%) HP:0003259
10 bone pain 59 32 frequent (33%) Frequent (79-30%) HP:0002653
11 acute kidney injury 59 32 frequent (33%) Frequent (79-30%) HP:0001919
12 hyperproteinemia 59 32 frequent (33%) Frequent (79-30%) HP:0002152
13 increased circulating igg level 32 frequent (33%) HP:0003237
14 weight loss 59 32 occasional (7.5%) Occasional (29-5%) HP:0001824
15 paresthesia 59 32 occasional (7.5%) Occasional (29-5%) HP:0003401
16 hypercalcemia 59 32 occasional (7.5%) Occasional (29-5%) HP:0003072
17 abnormality of the bladder 59 32 occasional (7.5%) Occasional (29-5%) HP:0000014
18 tall stature 59 32 occasional (7.5%) Occasional (29-5%) HP:0000098
19 functional abnormality of the gastrointestinal tract 59 32 occasional (7.5%) Occasional (29-5%) HP:0012719
20 vertebral compression fractures 59 32 occasional (7.5%) Occasional (29-5%) HP:0002953
21 spinal cord compression 59 32 occasional (7.5%) Occasional (29-5%) HP:0002176
22 abnormality of vitamin b12 metabolism 59 32 occasional (7.5%) Occasional (29-5%) HP:0004341
23 increased circulating iga level 32 occasional (7.5%) HP:0003261
24 splenomegaly 59 32 very rare (1%) Very rare (<4-1%) HP:0001744
25 lymphadenopathy 59 32 very rare (1%) Very rare (<4-1%),Frequent (79-30%) HP:0002716
26 pleural effusion 59 32 very rare (1%) Very rare (<4-1%),Occasional (29-5%) HP:0002202
27 multiple myeloma 59 32 Frequent (79-30%) HP:0006775
28 osteoarthritis 59 Occasional (29-5%)
29 hypertension 59 Occasional (29-5%)
30 constipation 59 Frequent (79-30%)
31 macroglossia 59 Occasional (29-5%)
32 hepatomegaly 59 Frequent (79-30%)
33 malabsorption 59 Occasional (29-5%)
34 renal insufficiency 59 Frequent (79-30%)
35 proteinuria 59 Frequent (79-30%)
36 arthralgia 59 Frequent (79-30%)
37 hypertrophic cardiomyopathy 59 Very frequent (99-80%)
38 dyspnea 59 Frequent (79-30%)
39 arrhythmia 59 Frequent (79-30%)
40 hepatitis 59 Occasional (29-5%)
41 abnormal blistering of the skin 59 Occasional (29-5%)
42 papule 59 Occasional (29-5%)
43 congestive heart failure 59 Frequent (79-30%)
44 xerostomia 59 Occasional (29-5%)
45 hematuria 59 Occasional (29-5%)
46 gastrointestinal hemorrhage 59 Occasional (29-5%)
47 goiter 59 Occasional (29-5%)
48 keratoconjunctivitis sicca 59 Occasional (29-5%)
49 purpura 59 Occasional (29-5%)
50 increased igg level 59 Frequent (79-30%)

Symptoms via clinical synopsis from OMIM:

57
Laboratory Abnormalities:
paraproteinemia
high m-component
monoclonal gammopathy
primary immunoglobulin-related amyloidosis (al)

Neoplasia:
multiple myeloma

Clinical features from OMIM:

254500

GenomeRNAi Phenotypes related to Myeloma, Multiple according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased cell migration GR00055-A-1 9.55 BRAF CDK4 FGFR3 HRAS KRAS
2 Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance GR00210-A 9.35 CDK4 FGFR3 HRAS NRAS PTPN11
3 Reduced mammosphere formation GR00396-S 9.23 BRAF CCND1 CDK4 HRAS IDH2 KRAS

MGI Mouse Phenotypes related to Myeloma, Multiple:

46 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 10.18 BRAF CCND1 CDK4 FGFR3 HRAS KRAS
2 endocrine/exocrine gland MP:0005379 10.11 BRAF CCND1 CDK4 HRAS KRAS LIG4
3 neoplasm MP:0002006 10.11 BRAF CCND1 CDK4 FGFR3 HRAS IDH2
4 craniofacial MP:0005382 10.1 BRAF CCND1 FGFR3 HRAS KRAS NRAS
5 integument MP:0010771 10.09 BRAF CCND1 CDK4 FGFR3 HRAS KRAS
6 normal MP:0002873 9.97 BRAF CCND1 CDK4 FGFR3 HRAS KRAS
7 liver/biliary system MP:0005370 9.95 BRAF CDK4 KRAS LIG4 NRAS PTPN11
8 respiratory system MP:0005388 9.76 BRAF CCND1 FGFR3 HRAS IDH1 KRAS
9 pigmentation MP:0001186 9.73 BRAF CDK4 KRAS NRAS PTPN11 TP53
10 skeleton MP:0005390 9.61 BRAF CCND1 FGFR3 HRAS IDH1 KRAS
11 vision/eye MP:0005391 9.23 BRAF CCND1 CDK4 FGFR3 KRAS NRAS

Drugs & Therapeutics for Myeloma, Multiple

Drugs for Myeloma, Multiple (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 676)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Apixaban Approved Phase 4 503612-47-3 10182969
2
Phentolamine Approved Phase 4 50-60-2 5775
3
Penicillin G Approved, Vet_approved Phase 4 61-33-6 5904
4
Tobramycin Approved, Investigational Phase 4 32986-56-4 36294 5496
5
Sargramostim Approved, Investigational Phase 4 83869-56-1, 123774-72-1
6
Pirarubicin Investigational Phase 4 72496-41-4
7 Anti-HIV Agents Phase 4
8 Anti-Retroviral Agents Phase 4
9 Plerixafor octahydrochloride Phase 4
10 Antithrombin III Phase 4
11 Serine Proteinase Inhibitors Phase 4
12 Factor Xa Inhibitors Phase 4
13 Antithrombins Phase 4
14 Penicillin G Benzathine Phase 4
15 Penicillin G Procaine Phase 4
16 penicillins Phase 4
17 Mitogens Phase 4
18 Hematinics Phase 4
19 Epoetin alfa Phase 4 113427-24-0
20 Ferric Compounds Phase 4
21
Lomustine Approved, Investigational Phase 3 13010-47-4 3950
22
Cobalt Approved, Experimental Phase 3 7440-48-4 104729
23
Pamidronate Approved Phase 3 40391-99-9 4674
24
Itraconazole Approved, Investigational Phase 3 84625-61-6 55283
25
Trimethoprim Approved, Vet_approved Phase 3 738-70-5 5578
26
Sulfamethoxazole Approved Phase 3 723-46-6 5329
27
Epirubicin Approved Phase 3 56420-45-2 41867
28
Ethanol Approved Phase 3 64-17-5 702
29
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
30
Modafinil Approved, Investigational Phase 3 68693-11-8 4236
31
Calcium carbonate Approved, Investigational Phase 3 471-34-1
32
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
33
Dextromethorphan Approved Phase 3 125-71-3 5360696 5362449
34
Ifosfamide Approved Phase 3 3778-73-2 3690
35
Ciprofloxacin Approved, Investigational Phase 3 85721-33-1 2764
36
Caspofungin Approved Phase 3 179463-17-3, 162808-62-0 468682 2826718
37
Amphotericin B Approved, Investigational Phase 3 1397-89-3 14956 5280965
38
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
39
Nystatin Approved, Vet_approved Phase 3 1400-61-9 11953884
40
deoxycholic acid Approved Phase 3 83-44-3 222528
41
Amitriptyline Approved Phase 3 50-48-6 2160
42
Carvedilol Approved, Investigational Phase 3 72956-09-3 2585
43
Enalapril Approved, Vet_approved Phase 3 75847-73-3 5362032 40466924
44
Enalaprilat Approved Phase 3 76420-72-9 6917719
45
Ribavirin Approved Phase 3 36791-04-5 37542
46
Palivizumab Approved, Investigational Phase 3 188039-54-5
47
Captopril Approved Phase 3 62571-86-2 44093
48
Tazobactam Approved Phase 3 89786-04-9 123630
49
Piperacillin Approved Phase 3 66258-76-2 43672
50
Vancomycin Approved Phase 3 1404-90-6 441141 14969

Interventional clinical trials:

(show top 50) (show all 2798)
# Name Status NCT ID Phase Drugs
1 A Multicenter, Double Arms, Prospective Phase 4 Study to Evaluating the Efficacy and Safety of Combination Therapy of PAD Versus VCD Treatment in Previously Untreated Subjects With Multiple Myeloma. Unknown status NCT01868828 Phase 4 PAD;VCD
2 Study of Efficacy of PAD-regimen(Bortezomib,Pirarubicin and Dexamethasone) and TAD-regimen(Thalidomide,Pirarubicin and Dexamethasone) in Newly Diagnosed Multiple Myeloma,Influence in Concentration of Bone Metabolites,and the Relations With Different Cytogenetic and Molecular Biological Changes Unknown status NCT01249690 Phase 4 Bortezomib,Pirarubicin,Dexamethasone;Thalidomide,Pirarubicin,Dexamethasone
3 Stage I Multiple Myeloma Treatment Unknown status NCT00733538 Phase 4 zometa
4 Clinical, Multicenter, Single-arm, Treatment With a Scheme With Low Doses of Bortezomib / Melphalan / Prednisone (MPV) in Patients With Multiple Myeloma (MM) Newly Diagnosed Symptomatic ≥75 Years Unknown status NCT02773550 Phase 4 Bortezomib;Melphalan;Prednisone
5 A Randomized Clinical Trial of Lenalidomide (CC-5013) and Dexamethasone With and Without Autologous Peripheral Blood Stem Cell Transplant in Patients With Newly Diagnosed Multiple Myeloma Completed NCT01731886 Phase 4 Lenalidomide;Dexamethasone;Melphalan;G-CSF;Cyclophosphamide;Mesna
6 Bone Marker Directed Dosing of Zoledronic Acid for the Prevention of Skeletal Complications in Patients With Advanced Multiple Myeloma Completed NCT00622505 Phase 4 zoledronic acid
7 Thalidomide-Cyclophosphamide-Dexamethasone in Patients < 75 Years or Velcade-Melfalan-Prednisone (V-MP)/Thalidomide-Cyclophosphamide-Dexamethasone in Patients >75 Years, in Refractary or Relapsed Multiple Myeloma Completed NCT00652041 Phase 4 Bortezomib;Thalidomide;Bortezomib
8 A Multicenter,Open Label, Randomized Trial Evaluating the Duration of Infusion of Zoledronic Acid 4 mg IV in Multiple Myeloma Patients With Bone Metastases Completed NCT00104104 Phase 4 zoledronic acid
9 Evaluation of VELCADE (Botezomib) for Injection Employed as Re-Treatment for Efficacy, Safety, and Tolerability Completed NCT00257114 Phase 4 bortezomib
10 A Phase IV Study of Zoledronic Acid Therapy in Patients With Bone Metastases From Breast Cancer or Hormone Resistant Prostate Cancer, or Bone Involvement From Multiple Myeloma, Assessing Long-term Efficacy and Safety Completed NCT00434447 Phase 4 Zoledronic acid
11 Pharmacokinetic Study of Bortezomib (VELCADE) Administered Intravenously in Taiwanese Patients With Multiple Myeloma - A Post Approval Commitment Study Completed NCT02268890 Phase 4 Bortezomib
12 An Open-label, Single-arm Study of Palifermin for Reduction of Mucositis in Subjects With Non-Hodgkin's Lymphoma or Multiple Myeloma Undergoing High-Dose Chemotherapy and Autologous Peripheral Blood Stem Cell (PBSC) Transplantation Completed NCT00352703 Phase 4 Kepivance (Palifermin)
13 An International Multicentric, Multidisciplinary Prospective and Randomized Study to Compare Minimally Invasive Reduction and Fixation Using the KyphX System and Radiopaque PMMA Cement to Medical Therapy Alone for the Treatment of Painful, Acute Osteopenic Vertebral Body Compression Fractures Completed NCT00211211 Phase 4
14 The Effects of PROCRIT (Epoetin Alfa) on Hemoglobin, Symptom Distress, and Quality of Life During Chemotherapy in Lymphoma, Chronic Lymphocytic Leukemia or Multiple Myeloma Patients With Mild to Moderate Anemia Completed NCT00524407 Phase 4 Epoetin alfa
15 Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma Receiving Immunomodulatory Therapy Completed NCT02958969 Phase 4 Apixaban;Placebo Oral Tablet
16 Evaluation of Allogeneic Marrow Transplants Depleted of T-Cells by CD34+ Selection in Patients Undergoing Transplantation With an Unrelated Matched or 1 Antigen Mismatched Donor or a 1 Antigen Mismatched Related Donor Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
17 REmoval of Free Light Chains in Hemodialysis Patients Without Multiple Myeloma. A Crossover COmpaRison of Three Different dialyzERs Completed NCT02950389 Phase 4
18 Tobramycin én Gang Daglig Mot Tre Ganger Daglig, Gitt Med Benzylpenicillin, Til Pasienter Med nøytropen Feber Completed NCT00257790 Phase 4 Tobramycin once a day
19 Mobilization Test of BM Progenitor Cells With Plerixafor / AMD3100: Controlled Parallel Group Comparison Between Diabetic and Non Diabetic Subjects Completed NCT02056210 Phase 4 Mozobil
20 RDD Versus VDD Followed by ASCT in Newly Diagnosed Young Patients With Multiple Myeloma Recruiting NCT03908138 Phase 4 RDD;VDD
21 Doxorubicin Hydrochloride Liposome vs Doxorubicin Combined With Bortizomib and Dexamethasone to Treat Initially Diagnosed Multiple Myeloma: A Randomized Prospective Clinical Study Recruiting NCT02577783 Phase 4 PDD regimen: doxorubicin hydrochloride iposome, bortizomib and dexamethasone;PAD regimen: bortizomib, dexamethasone and doxorubicin
22 A Prospective, Single-Arm, Multicenter, Pragmatic Phase-IV Trial Investigating Safety and Effectiveness of DARZALEX (Daratumumab) In Indian Subjects With Relapsed and Refractory Multiple Myeloma, Whose Prior Therapy Included a Proteasome Inhibitor and an Immunomodulatory Agent Recruiting NCT03768960 Phase 4 Daratumumab
23 Magnolia Study Prolonged Protection From Bone Disease in Multiple Myeloma. An Open Label Phase 3 Multicenter International Randomised Trial Recruiting NCT02286830 Phase 4 Zoledronic acid
24 An Open-label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Ixazomib in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma Initially Treated With an Injection of Proteasome Inhibitor-Based Therapy Recruiting NCT03416374 Phase 4 Ixazomib;Bortezomib;Carfilzomib;Lenalidomide;Dexamethasone
25 An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) in Patients With Multiple Myeloma Previously Receiving a Bortezomib-Based Induction Regimen (US MM-6) Recruiting NCT03173092 Phase 4 Ixazomib;Lenalidomide;Dexamethasone
26 A RANDOMIZED, MULTICENTER, OPEN LABEL STUDY COMPARING TWO STANDARD TREATMENTS, BORTEZOMIB-MELPHALAN-PREDNISONE (VMP) VS LENALIDOMIDE-DEXAMETHASONE (Rd) IN AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) INELIGIBLE COMMUNITY POPULATION AFFECTED BY MULTIPLE MYELOMA (MM) Recruiting NCT03829371 Phase 4 Velcade;Melphalan;Prednisone;Lenalidomide;Dexamethasone
27 An Open-Label Phase IV Study of the Efficacy of Bortezomib-based Combination Therapy the Treatment of Subjects With Multiple Myeloma Active, not recruiting NCT02559154 Phase 4 Bortezomib;Dexamethasone;Doxorubicin;Cyclophosphamide;Mitoxsnteone;Thalidomide
28 Assessment of the Antitumour Effect of Zoledronic Acid in Patients With Multiple Myeloma and Asymptomatic Biochemical Relapse: Prospective Clinical Trial of the GEM/PETHEMA Group Active, not recruiting NCT01087008 Phase 4 zoledronic acid
29 Pneumococcal Vaccination of Multiple Myeloma Patients on Novel Agents Enrolling by invitation NCT03619252 Phase 4 Standard Antibacterial Prophylaxis
30 Post-marketing Phase 4 Study to Evaluate Safety, Tolerability, and Efficacy of Kyprolis® (Carfilzomib) in Indian Patients With Relapsed or Refractory Multiple Myeloma: A Prospective, Open-label, Non-comparative, Multicenter Study Not yet recruiting NCT03934684 Phase 4 Drug: Carfilzomib + Dexamethasone;Drug: Carfilzomib + Lenalidomide + Dexamethasone
31 A Pilot Study to Evaluate 18F Florbetapir Binding to Cardiac Amyloid in Patients Undergoing Chemotherapy Not yet recruiting NCT03333551 Phase 4 F18 Florbetapir (amyvid) cardiac PET/CT imaging
32 Randomised Controlled Open-label Study to Evaluate Efficacy & Safety of Intravenous Ferric Carboxymaltose Versus no Treatment in Anaemic Subjects With Multiple Myeloma & Iron Restricted Erythropoiesis Receiving Chemotherapy Terminated NCT01100879 Phase 4 Ferric carboxymaltose
33 Open Multicentric Study to Assess the Hematopoyetic Response in Terms of Increase of Hemoglobin Levels of Patients With Anemia Related to Non- Hodgkin Lymphoma, Chronic Lymphocytic Leukemia or Multiple Myeloma, Treated With Erythropoietin B (Recormon) Using Pre-filled Syringe With 30000 IU, as Well as to Quantify the Risk Factors of Anemia and Its Impact on Quality of Life Related to Treatment Terminated NCT02608060 Phase 4 Epoetin Beta
34 Subcutaneous (SC) vs. Intravenous (IV) Granulocyte Colony Stimulating Factors (G-CSF) for the Treatment of Neutropenia in Hospitalized Haemato-oncological Patients: Randomized Controlled Trial Terminated NCT01222819 Phase 4 filgrastim
35 Open-label Study, to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Bone Lesions Secondary to Multiple Myeloma. Withdrawn NCT00242528 Phase 4 Zoledronic acid
36 Evaluation of Vertebral Compression Fracture Fixation With RF Kyphoplasty in Patients With Multiple Myeloma Withdrawn NCT01410929 Phase 4
37 A Randomised Study Comparing CIDEX (CCNU, Oral Idarubicin and Dexamethasone) With Melphalan and Prednisolone in Relapsed Multiple Myeloma Unknown status NCT00003603 Phase 3 cyclophosphamide;dexamethasone;idarubicin;lomustine;melphalan;prednisolone
38 A Randomized, Phase III, Placebo-Controlled Multicenter Study to Demonstrate the Effectiveness and Safety of the Combination Enzyme Tablet (Wobe-Mugos E) as Adjuvant Therapy to Standard of Care Treatment in Patients With Stages II or III Multiple Myeloma Unknown status NCT00014339 Phase 3 Wobe-Mugos E;melphalan;prednisone
39 A Multicenter, Single-arm, Open-label Study to Evaluate the Efficacy and Safety of Pomalidomide in Combination With Low-dose Dexamethasone in Chinese Patients With Relapsed and Refractory Multiple Myeloma Unknown status NCT02916420 Phase 3 Pomalidomide;Dexamethasone
40 Study on the Incidence of Febrile Episodes During Stem Cells Collection After Chemotherapy in Patients With Multiple Myeloma Unknown status NCT00932217 Phase 3 filgrastim;lenograstim
41 A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation Compare With Allogeneic Bone Marrow Transplantation in Multiple Myeloma Unknown status NCT00998270 Phase 2, Phase 3
42 A Phase 3 Study of Velcade (Bortezomib) Dexamethasone (VD) Versus Velcade (Bortezomib) Thalidomide Dexamethasone (VTD) as an Induction Treatment Prior to Autologous Stem Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma Unknown status NCT00910897 Phase 3 Velcade-Dexamethasone;Velcade-Thalidomide-Dexamethasone
43 VIIITH MYELOMATOSIS TRIAL: A RANDOMISED TRIAL OF TREATMENT FOR INDUCING FIRST PLATEAU PHASE ABCM VS 3 COURSES OF ABCM FOLLOWED BY ORAL WEEKLY CYCLOPHOSPHAMIDE Unknown status NCT00002653 Phase 3 carmustine;cyclophosphamide;doxorubicin hydrochloride;melphalan;prednisone
44 Hematopoietic Stem Cell Transplantation in Myeloma Unknown status NCT00415987 Phase 2, Phase 3
45 A Phase 3 Trial Comparing Cyclophosphamide,Bortezomib,and Dexamethasone (CyBorD) and Bortezomib,Doxorubicin,and Dexamethasone (PAD) in the Treatment of Newly Diagnosed Multiple Myeloma Unknown status NCT02362165 Phase 3 Cyclophosphamide;Bortezomib;Dexamethasone;Doxorubicin
46 MYELOMA VII MEDICAL RESEARCH COUNCIL WORKING PARTY ON LEUKEMIA IN ADULTS: MYELOMATOSIS THERAPY TRIAL Unknown status NCT00002599 Phase 3 carmustine;cyclophosphamide;doxorubicin hydrochloride;melphalan;methylprednisolone;prednisone;vincristine sulfate
47 Comparable Investigation of One Fraction Radiotherapy (8 Gy x 1) and Multifraction Radiotherapy (3 Gy x 10) of Painful Bone Destructions in Patients With Multiple Myeloma. Unknown status NCT02024815 Phase 3
48 Myeloma X Relapse (Intensive): A Phase III Study to Determine the Role of a Second Autologous Stem Cell Transplant as Consolidation Therapy in Patients With Relapsed Multiple Myeloma Following Prior High-dose Chemotherapy and Autologous Stem Cell Rescue. Unknown status NCT00747877 Phase 3 cyclophosphamide;melphalan
49 A Randomized Double-Blind Controlled Trial of Ketamine Versus Placebo in Conjunction With Best Pain Management in Neuropathic Pain in Cancer Patients Unknown status NCT01316744 Phase 3 ketamine hydrochloride
50 Phase 3 Study to Evaluate Bortezomib Induced Peripheral Neuropathy of Multiple Myeloma (MM) Patients. Unknown status NCT00872352 Phase 3

Search NIH Clinical Center for Myeloma, Multiple

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Aldesleukin
bortezomib
Bortezomib
carfilzomib
Carmustine
Cisplatin
Cisplatin
CISPLATIN PWDR
Cyclophosphamide
Cyclophosphamide
Daratumumab
Doxorubicin
Etoposide
Interferon Alfa-2a
Interferon Alfa-2b
INTERFERON ALFA-3N,HUMAN LEUKOCYTE DERIVED
interferon alfacon-1
Interferon gamma-1b
Interferons
Ixazomib
Lenalidomide
Melphalan
Melphalan
Melphalan hydrochloride
panobinostat
peginterferon alfa-2a
peginterferon alfa-2b
Procarbazine
Procarbazine Hydrochloride
Recombinant interferon beta-1a
Recombinant interferon beta-1b
Thalidomide
Thalidomide
Vincristine
ZOLEDRONIC
zoledronic acid

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Myeloma, Multiple cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: multiple myeloma

Genetic Tests for Myeloma, Multiple

Genetic tests related to Myeloma, Multiple:

# Genetic test Affiliating Genes
1 Multiple Myeloma 29 CCND1 LIG4

Anatomical Context for Myeloma, Multiple

MalaCards organs/tissues related to Myeloma, Multiple:

41
Bone, Bone Marrow, T Cells, B Cells, Kidney, Testes, Myeloid
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Myeloma, Multiple:
# Tissue Anatomical CompartmentCell Relevance
1 Blood Hematopoietic Bone Marrow Hematopoietic Stem Cells Potential therapeutic candidate
2 Blood Peripheral Blood Mature B-Cells Affected by disease

Publications for Myeloma, Multiple

Articles related to Myeloma, Multiple:

(show top 50) (show all 30050)
# Title Authors PMID Year
1
Genetic variants of NHEJ DNA ligase IV can affect the risk of developing multiple myeloma, a tumour characterised by aberrant class switch recombination. 38 8 71
12471202 2002
2
Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. 38 8 71
9207791 1997
3
Genetic Predisposition to Multiple Myeloma at 5q15 Is Mediated by an ELL2 Enhancer Polymorphism. 38 8
28903037 2017
4
BCL-B (BCL2L10) is overexpressed in patients suffering from multiple myeloma (MM) and drives an MM-like disease in transgenic mice. 38 8
27455953 2016
5
The CCND1 c.870G>A polymorphism is a risk factor for t(11;14)(q13;q32) multiple myeloma. 38 8
23502783 2013
6
Initial genome sequencing and analysis of multiple myeloma. 38 8
21430775 2011
7
Multiple myeloma. 38 8
21410373 2011
8
Association of a dominantly inherited hyperphosphorylated paraprotein target with sporadic and familial multiple myeloma and monoclonal gammopathy of undetermined significance: a case-control study. 38 8
19767238 2009
9
A frequent target of paraproteins in the sera of patients with multiple myeloma and MGUS. 38 8
19405124 2009
10
Bisphosphonate-related osteonecrosis of the jaw is associated with polymorphisms of the cytochrome P450 CYP2C8 in multiple myeloma: a genome-wide single nucleotide polymorphism analysis. 38 8
18594024 2008
11
Familial myeloma. 38 8
18614782 2008
12
IRF4 addiction in multiple myeloma. 38 8
18568025 2008
13
Chromosome aberrations in a series of 120 multiple myeloma cases with abnormal karyotypes. 38 8
17654686 2007
14
Translocations of 14q32 and deletions of 13q14 are common chromosomal abnormalities in systemic amyloidosis. 38 8
11972529 2002
15
Analysis of FGFR3 gene mutations in multiple myeloma patients with t(4;14). 38 71
11529856 2001
16
Familial multiple myeloma: report of fifteen families. 38 8
10354144 1999
17
Deregulation of MUM1/IRF4 by chromosomal translocation in multiple myeloma. 38 8
9326949 1997
18
Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma. 38 8
8943038 1996
19
Multiple myeloma in a pair of twins. 38 8
3814524 1987
20
Primary amyloidosis (AL) in families. 38 8
3706293 1986
21
Multiple myeloma in three siblings. 38 8
3927866 1985
22
Multiple myeloma in a pair of monozygotic twins: the first reported case. 38 8
3925983 1985
23
Familial immunopathies: report of nine families and survey of literature. 38 8
336182 1977
24
MULTIPLE MYELOMA IN SIBLINGS. 38 8
14180901 1964
25
KORNGOLD L: MULTIPLE MYELOMA IN 2 SISTERS. AN IMMUNOCHEMICAL STUDY. 38 8
14172080 1964
26
Multiple myeloma in sisters. 38 8
13766287 1961
27
Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. 38 17
31171419 2019
28
Multiple myeloma: Every year a new standard? 38 17
31187526 2019
29
Chimeric Antigen Receptor T-Cell Therapy: Reach to Solid Tumor Experience. 38 17
31261152 2019
30
Identification of microRNA expression patterns and definition of a microRNA/mRNA regulatory network in distinct molecular groups of multiple myeloma. 38 88
19846888 2009
31
Activating mutations in FGFR3 and HRAS reveal a shared genetic origin for congenital disorders and testicular tumors. 71
19855393 2009
32
MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma. 38 88
19401561 2009
33
MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis. 38 88
18728182 2008
34
An epidermal nevus syndrome with cerebral involvement caused by a mosaic FGFR3 mutation. 71
18642369 2008
35
An integrative genomic approach reveals coordinated expression of intronic miR-335, miR-342, and miR-561 with deregulated host genes in multiple myeloma. 38 88
18700954 2008
36
Mosaicism of activating FGFR3 mutations in human skin causes epidermal nevi. 71
16841094 2006
37
Thanatophoric dysplasia type 2 with encephalocele during the second trimester. 71
16752380 2006
38
Activating mutations of the tyrosine kinase receptor FGFR3 are associated with benign skin tumors in mice and humans. 71
15772091 2005
39
Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study. 8
14739213 2004
40
Somatic and germline mosaicism for a R248C missense mutation in FGFR3, resulting in a skeletal dysplasia distinct from thanatophoric dysplasia. 71
12833394 2003
41
The thanatophoric dysplasia type II mutation hampers complete maturation of fibroblast growth factor receptor 3 (FGFR3), which activates signal transducer and activator of transcription 1 (STAT1) from the endoplasmic reticulum. 71
12624096 2003
42
Prenatal diagnosis of thanatophoric dysplasia by mutational analysis of the fibroblast growth factor receptor 3 gene and a proposed correction of previously published PCR results. 71
10073901 1999
43
Anticipation in familial plasma cell dyscrasias. 8
9858219 1998
44
Molecular, radiologic, and histopathologic correlations in thanatophoric dysplasia. 71
9677066 1998
45
Cdkn2a, the cyclin-dependent kinase inhibitor encoding p16INK4a and p19ARF, is a candidate for the plasmacytoma susceptibility locus, Pctr1. 8
9482902 1998
46
The systemic amyloidoses. 8
9302305 1997
47
Japanese cases of type 1 thanatophoric dysplasia exclusively carry a C to T transition at nucleotide 742 of the fibroblast growth factor receptor 3 gene. 71
8858131 1996
48
Familial AL-amyloidosis in three Italian siblings. 8
8641636 1996
49
Thanatophoric dysplasia (types I and II) caused by distinct mutations in fibroblast growth factor receptor 3. 71
7773297 1995
50
IgM monoclonal gammopathy and neuropathy in two siblings. 8
2852210 1988

Variations for Myeloma, Multiple

ClinVar genetic disease variations for Myeloma, Multiple:

6 (show top 50) (show all 146)
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 TP53 NM_000546.5(TP53): c.832C> A (p.Pro278Thr) single nucleotide variant Likely pathogenic,drug response rs17849781 17:7577106-7577106 17:7673788-7673788
2 CDK4 NM_000075.4(CDK4): c.71G> A (p.Arg24His) single nucleotide variant Likely pathogenic,risk factor rs104894340 12:58145430-58145430 12:57751647-57751647
3 CDK4 NM_000075.4(CDK4): c.70C> T (p.Arg24Cys) single nucleotide variant Pathogenic rs11547328 12:58145431-58145431 12:57751648-57751648
4 FGFR3 NM_000142.4(FGFR3): c.742C> T (p.Arg248Cys) single nucleotide variant Pathogenic rs121913482 4:1803564-1803564 4:1801837-1801837
5 FGFR3 NM_000142.4(FGFR3): c.1948A> G (p.Lys650Glu) single nucleotide variant Pathogenic rs78311289 4:1807889-1807889 4:1806162-1806162
6 BRAF NM_004333.6(BRAF): c.1406G> A (p.Gly469Glu) single nucleotide variant Pathogenic rs121913355 7:140481402-140481402 7:140781602-140781602
7 BRAF NM_004333.6(BRAF): c.1781A> G (p.Asp594Gly) single nucleotide variant Pathogenic rs121913338 7:140453154-140453154 7:140753354-140753354
8 BRAF NM_004333.6(BRAF): c.1405G> C (p.Gly469Arg) single nucleotide variant Pathogenic rs121913357 7:140481403-140481403 7:140781603-140781603
9 PTPN11 NM_002834.4(PTPN11): c.227A> C (p.Glu76Ala) single nucleotide variant Pathogenic rs121918465 12:112888211-112888211 12:112450407-112450407
10 PTPN11 NM_002834.4(PTPN11): c.227A> G (p.Glu76Gly) single nucleotide variant Pathogenic rs121918465 12:112888211-112888211 12:112450407-112450407
11 PTPN11 NM_002834.4(PTPN11): c.226G> A (p.Glu76Lys) single nucleotide variant Pathogenic rs121918464 12:112888210-112888210 12:112450406-112450406
12 HRAS NM_005343.4(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic rs104894229 11:534289-534289 11:534289-534289
13 HRAS NM_005343.4(HRAS): c.37G> T (p.Gly13Cys) single nucleotide variant Pathogenic rs104894228 11:534286-534286 11:534286-534286
14 HRAS NM_005343.4(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic rs104894230 11:534288-534288 11:534288-534288
15 HRAS NM_005343.4(HRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs104894229 11:534289-534289 11:534289-534289
16 TP53 NM_000546.5(TP53): c.842A> G (p.Asp281Gly) single nucleotide variant Pathogenic rs587781525 17:7577096-7577096 17:7673778-7673778
17 TP53 NM_000546.5(TP53): c.422G> A (p.Cys141Tyr) single nucleotide variant Pathogenic rs587781288 17:7578508-7578508 17:7675190-7675190
18 NRAS NM_002524.5(NRAS): c.35G> T (p.Gly12Val) single nucleotide variant Pathogenic rs121913237 1:115258747-115258747 1:114716126-114716126
19 NRAS NM_002524.5(NRAS): c.34G> C (p.Gly12Arg) single nucleotide variant Pathogenic rs121913250 1:115258748-115258748 1:114716127-114716127
20 NRAS NM_002524.5(NRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic rs121913250 1:115258748-115258748 1:114716127-114716127
21 BRAF NM_004333.6(BRAF): c.1787G> T (p.Gly596Val) single nucleotide variant Pathogenic rs397507483 7:140453148-140453148 7:140753348-140753348
22 TP53 NM_000546.5(TP53): c.833C> T (p.Pro278Leu) single nucleotide variant Pathogenic rs876659802 17:7577105-7577105 17:7673787-7673787
23 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic rs121912651 17:7577539-7577539 17:7674221-7674221
24 TP53 NM_000546.5(TP53): c.818G> T (p.Arg273Leu) single nucleotide variant Pathogenic rs28934576 17:7577120-7577120 17:7673802-7673802
25 TP53 NM_000546.5(TP53): c.841G> A (p.Asp281Asn) single nucleotide variant Pathogenic rs764146326 17:7577097-7577097 17:7673779-7673779
26 NRAS NM_002524.5(NRAS): c.182A> C (p.Gln61Pro) single nucleotide variant Pathogenic rs11554290 1:115256529-115256529 1:114713908-114713908
27 NRAS NM_002524.5(NRAS): c.182A> G (p.Gln61Arg) single nucleotide variant Pathogenic rs11554290 1:115256529-115256529 1:114713908-114713908
28 NRAS NM_002524.5(NRAS): c.38G> A (p.Gly13Asp) single nucleotide variant Pathogenic rs121434596 1:115258744-115258744 1:114716123-114716123
29 BRAF NM_004333.6(BRAF): c.1799T> A (p.Val600Glu) single nucleotide variant Pathogenic rs113488022 7:140453136-140453136 7:140753336-140753336
30 BRAF NM_004333.6(BRAF): c.1406G> C (p.Gly469Ala) single nucleotide variant Pathogenic rs121913355 7:140481402-140481402 7:140781602-140781602
31 IDH2 NM_002168.3(IDH2): c.419G> A (p.Arg140Gln) single nucleotide variant Pathogenic rs121913502 15:90631934-90631934 15:90088702-90088702
32 FGFR3 FGFR3, FGFR3/IGH FUSION undetermined variant Pathogenic
33 NRAS NM_002524.5(NRAS): c.35G> A (p.Gly12Asp) single nucleotide variant Pathogenic rs121913237 1:115258747-115258747 1:114716126-114716126
34 BRAF NM_004333.6(BRAF): c.1406G> T (p.Gly469Val) single nucleotide variant Pathogenic rs121913355 7:140481402-140481402 7:140781602-140781602
35 NRAS NM_002524.5(NRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs121913250 1:115258748-115258748 1:114716127-114716127
36 TP53 NM_000546.5(TP53): c.584T> C (p.Ile195Thr) single nucleotide variant Pathogenic rs760043106 17:7578265-7578265 17:7674947-7674947
37 NRAS NM_002524.5(NRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic rs121913237 1:115258747-115258747 1:114716126-114716126
38 NRAS NM_002524.5(NRAS): c.183A> T (p.Gln61His) single nucleotide variant Pathogenic rs121913255 1:115256528-115256528 1:114713907-114713907
39 TP53 NM_000546.5(TP53): c.713G> T (p.Cys238Phe) single nucleotide variant Pathogenic rs730882005 17:7577568-7577568 17:7674250-7674250
40 TP53 NM_000546.5(TP53): c.712T> C (p.Cys238Arg) single nucleotide variant Pathogenic rs1057519981 17:7577569-7577569 17:7674251-7674251
41 TP53 NM_000546.5(TP53): c.841G> T (p.Asp281Tyr) single nucleotide variant Pathogenic rs764146326 17:7577097-7577097 17:7673779-7673779
42 NRAS NM_002524.5(NRAS): c.38G> T (p.Gly13Val) single nucleotide variant Pathogenic/Likely pathogenic rs121434596 1:115258744-115258744 1:114716123-114716123
43 KRAS NM_004985.5(KRAS): c.351A> C (p.Lys117Asn) single nucleotide variant Pathogenic/Likely pathogenic rs770248150 12:25378647-25378647 12:25225713-25225713
44 TP53 NM_000546.5(TP53): c.842A> T (p.Asp281Val) single nucleotide variant Pathogenic/Likely pathogenic rs587781525 17:7577096-7577096 17:7673778-7673778
45 LIG4 NM_002312.3(LIG4): c.2440C> T (p.Arg814Ter) single nucleotide variant Pathogenic/Likely pathogenic rs104894419 13:108861177-108861177 13:108208829-108208829
46 TP53 NM_000546.5(TP53): c.451C> T (p.Pro151Ser) single nucleotide variant Pathogenic/Likely pathogenic rs28934874 17:7578479-7578479 17:7675161-7675161
47 BRAF NM_004333.6(BRAF): c.1790T> A (p.Leu597Gln) single nucleotide variant Pathogenic/Likely pathogenic rs121913366 7:140453145-140453145 7:140753345-140753345
48 IDH1 NM_005896.3(IDH1): c.395G> A (p.Arg132His) single nucleotide variant Pathogenic/Likely pathogenic rs121913500 2:209113112-209113112 2:208248388-208248388
49 IDH2 NM_002168.3(IDH2): c.418C> T (p.Arg140Trp) single nucleotide variant Pathogenic/Likely pathogenic rs267606870 15:90631935-90631935 15:90088703-90088703
50 IDH2 NM_002168.3(IDH2): c.419G> T (p.Arg140Leu) single nucleotide variant Pathogenic/Likely pathogenic rs121913502 15:90631934-90631934 15:90088702-90088702

Copy number variations for Myeloma, Multiple from CNVD:

7 (show top 50) (show all 303)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13351 1 1 125000000 Gain Multiple myeloma
2 14061 1 103799708 118390708 Loss Multiple myeloma
3 14338 1 107200000 120600000 Loss and deletion Multiple myeloma
4 16446 1 124300000 247249719 Rearrangement Multiple myeloma
5 17396 1 142600000 155000000 Gain Plasma-cell dyscrasia
6 17400 1 142600000 156500000 Gain and amplification Multiple myeloma
7 17467 1 142902432 245422432 Gain Multiple myeloma
8 20609 1 153300000 154800000 Gain AIM2 Multiple myeloma
9 20611 1 153300000 154800000 Gain EST1B Multiple myeloma
10 20700 1 1536308 6536308 Loss Multiple myeloma
11 20848 1 154800000 157300000 Gain UFC1 Multiple myeloma
12 20849 1 154800000 158800000 Gain CAPON Multiple myeloma
13 20882 1 155000000 156500000 Gain and amplification Multiple myeloma
14 26152 1 197500000 205300000 Gain CHI3L1 Multiple myeloma
15 26153 1 197500000 205300000 Gain PTPN7 Multiple myeloma
16 26162 1 197500000 222100000 Gain GUK1 Multiple myeloma
17 29497 1 23265113 23869113 Loss Multiple myeloma
18 29829 1 236600000 249250621 Gain and amplification Multiple myeloma
19 31636 1 2900000 120700000 Gain CD53 Multiple myeloma
20 31729 1 30200000 32400000 Loss and deletion Multiple myeloma
21 33943 1 50669458 53683458 Loss Multiple myeloma
22 33949 1 50700000 59000000 Loss and deletion Multiple myeloma
23 35189 1 60900000 69500000 Gain NFIA Multiple myeloma
24 36791 1 80821425 83677425 Loss Multiple myeloma
25 36969 1 84171854 96213854 Loss Multiple myeloma
26 37035 1 84700000 88100000 Gain Multiple myeloma
27 37040 1 84700000 94500000 Gain DISC1 Multiple myeloma
28 37519 1 9200000 12700000 Loss and deletion Multiple myeloma
29 37525 10 30762871 30790767 Gain EST Multiple myeloma
30 38898 10 105800000 114900000 Loss and deletion Multiple myeloma
31 40402 10 127500000 135534747 Loss and deletion Multiple myeloma
32 41379 10 17300000 22600000 Gain and amplificati on Multiple myeloma
33 48571 11 100828925 102320925 Loss ANGPTL5 Multiple myeloma
34 48572 11 100828925 102320925 Loss BIRC2 Multiple myeloma
35 48573 11 100828925 102320925 Loss BIRC3 Multiple myeloma
36 48574 11 100828925 102320925 Loss KIAA1377 Multiple myeloma
37 48575 11 100828925 102320925 Loss MMP1 Multiple myeloma
38 48576 11 100828925 102320925 Loss MMP10 Multiple myeloma
39 48577 11 100828925 102320925 Loss MMP12 Multiple myeloma
40 48578 11 100828925 102320925 Loss MMP13 Multiple myeloma
41 48579 11 100828925 102320925 Loss MMP20 Multiple myeloma
42 48580 11 100828925 102320925 Loss MMP27 Multiple myeloma
43 48581 11 100828925 102320925 Loss MMP3 Multiple myeloma
44 48582 11 100828925 102320925 Loss MMP7 Multiple myeloma
45 48583 11 100828925 102320925 Loss MMP8 Multiple myeloma
46 48584 11 100828925 102320925 Loss PORIMIN Multiple myeloma
47 48585 11 100828925 102320925 Loss TRPC6 Multiple myeloma
48 48586 11 100828925 102320925 Loss YAP1 Multiple myeloma
49 49668 11 110000000 112800000 Gain POU2AF1 Multiple myeloma
50 49996 11 112500000 121200000 Loss and deletion Multiple myeloma

Expression for Myeloma, Multiple

Search GEO for disease gene expression data for Myeloma, Multiple.

Pathways for Myeloma, Multiple

Pathways related to Myeloma, Multiple according to KEGG:

37
# Name Kegg Source Accession
1 Transcriptional misregulation in cancer hsa05202

Pathways related to Myeloma, Multiple according to GeneCards Suite gene sharing:

(show top 50) (show all 109)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.44 TP53 PTPN11 NRAS KRAS HRAS FGFR3
2
Show member pathways
13.14 TP53 NRAS KRAS HRAS FGFR3 BRAF
3
Show member pathways
13.06 TP53 NRAS KRAS HRAS FGFR3 CDK4
4
Show member pathways
13.04 TP53 NRAS KRAS HRAS CDK4 CCND1
5
Show member pathways
12.94 NRAS KRAS HRAS CCND1 BRAF
6
Show member pathways
12.92 NRAS KRAS HRAS FGFR3 BRAF
7
Show member pathways
12.92 PTPN11 NRAS KRAS HRAS FGFR3
8
Show member pathways
12.89 TP53 PTPN11 NRAS KRAS HRAS CDK4
9
Show member pathways
12.85 PTPN11 KRAS HRAS CCND1 BRAF
10 12.85 TP53 NRAS KRAS HRAS FGFR3 CDK4
11 12.84 TP53 NRAS KRAS HRAS FGFR3 BRAF
12
Show member pathways
12.83 TP53 NRAS KRAS HRAS CDK4 CCND1
13
Show member pathways
12.82 PTPN11 NRAS KRAS HRAS FGFR3 BRAF
14
Show member pathways
12.8 TP53 PTPN11 NRAS KRAS HRAS FGFR3
15
Show member pathways
12.79 TP53 PTPN11 NRAS KRAS HRAS BRAF
16
Show member pathways
12.76 TP53 NRAS KRAS HRAS BRAF
17 12.71 NRAS KRAS HRAS FGFR3 BRAF
18
Show member pathways
12.69 TP53 NRAS KRAS HRAS FGFR3 CDK4
19
Show member pathways
12.68 TP53 PTPN11 NRAS KRAS HRAS
20
Show member pathways
12.67 PTPN11 NRAS KRAS HRAS FGFR3 BRAF
21
Show member pathways
12.65 PTPN11 NRAS KRAS HRAS CDK4
22
Show member pathways
12.61 PTPN11 NRAS KRAS HRAS BRAF
23
Show member pathways
12.58 PTPN11 NRAS KRAS HRAS CCND1
24
Show member pathways
12.58 TP53 NRAS KRAS HRAS FGFR3 BRAF
25
Show member pathways
12.58 TP53 PTPN11 NRAS KRAS HRAS CCND1
26
Show member pathways
12.53 PTPN11 NRAS KRAS HRAS
27
Show member pathways
12.53 PTPN11 NRAS KRAS HRAS FGFR3
28
Show member pathways
12.53 TP53 NRAS KRAS HRAS FGFR3
29
Show member pathways
12.49 PTPN11 NRAS KRAS HRAS CCND1
30
Show member pathways
12.49 PTPN11 NRAS KRAS HRAS BRAF
31
Show member pathways
12.48 NRAS KRAS HRAS BRAF
32
Show member pathways
12.47 PTPN11 NRAS KRAS HRAS
33
Show member pathways
12.47 PTPN11 KRAS HRAS BRAF
34
Show member pathways
12.47 NRAS KRAS HRAS FGFR3 BRAF
35